Pasar al contenido principal

CONTRIBUCION DEL ESTILO DE VIDA A LA RESILIENCIA CEREBRAL

PID2019-111514RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ BARCELONABETA BRAIN RESEARCH CENTER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex and gender differences in cognitive resilience to aging and Alzheimer's disease

  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Boyle, Rory
  • Casaletto, Kaitlin
  • Anstey, Kaarin J.
  • Vila-Castelar, Clara
  • Colverson, Aaron
  • Palpatzis, Eleni
  • Eissman, Jaclyn M.
  • Kheng Siang Ng, Ted
  • Raghavan, Sheelakumari
  • Akinci, Muge
  • Vonk, Jet M. J.
  • Machado, Luiza S.
  • Zanwar, Preeti P.
  • Shrestha, Hom L.
  • Wagner, Maude
  • Tamburin, Stefano
  • Sohrabi, Hamid R.
  • Loi, Samantha
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Dubal, Dena B.
  • Vemuri, Prashanthi
  • Okonkwo, Ozioma
  • Hohman, Timothy J.
  • Ewers, Michael|||0000-0001-5231-1714
  • Buckley, Rachel|||0000-0002-5356-5537
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Psychological resilience trajectories after the COVID-19 pandemic: the role of lifestyle and psychosocial factors in a cohort at increased alzheimer's disease risk

  • Contador, Israel
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Fauria, Karine
  • Minguillón, Carolina
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
Purpose: This longitudinal cohort study evaluates whether lifestyle and psychosocial factors are associated with psychological resilience at two time points of COVID-19 pandemic. Moreover, we investigated the mediating role of perceived stress on these associations.Methods: A total of 677 cognitively unimpaired (CU) older adults at increased risk of Alzheimer's disease (AD) completed the Hospital Anxiety and Depression Scale (HADS). Based on the Reliable Change Index (RCI), HADS trajectories were defined at two intervals: (1) pre-pandemic-confinement (follow-up = 2,28 ± 0,84 years); (2) confinement-post-confinement (follow-up = 1,49 ± 0,12 years). Then, 4 trajectory groups were defined: Psychological Resilience (n = 448, stable or improve at both intervals), Descending (n = 84, stable/improve [interval 1]-worsen [interval 2]), Recovery (n = 59, worsening [interval 1], improvement [interval 2] ) and Non-resilient (n = 86, worsening at both intervals). Logistic regression models (LRM) were applied considering lifestyle (physical and leisure activities, sleep) and psychosocial factors (social relationships and emotional support) as predictors of psychological resilience trajectory (i.e., outcome) at both intervals. Finally, mediation analyses were carried out to test the effect of perceived stress on the relationships between the predictive factors and psychological resilience. Results: Our finding showed that most participants followed a psychological resilient trajectory (66,1%). LRMs indicated that higher physical activity level, a greater number of social interactions and longer sleep duration were significantly associated with a psychological resilience trajectory both at confinement and at the 1.5 years follow-up. Lastly, the mediation analyses suggested that these factors influence psychological resilience through the mitigation of perceived stress. Conclusion: These findings underscore the role of physical activity, social interactions and sleep quality to strengthen individuals' capacity to cope with stress during prolonged crisis such as the COVID-19 pandemic. These lifestyle and psychological factors may be valuable targets for public health strategies aimed to prevent mental health problems., Open access funding provided by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027. The ALFA study receives funding from "la Caixa" Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. EMAU receives funding from the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation-State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). OG-R receives funding from the Alzheimer's Association Research Fellowship Programme (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). GS-B is supported by the Spanish Ministry of Science and Innovation - State Research Agency. MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).I. Contador was supported by the European Union- "NextGenerationEU" through the Grant for the Requalification of the Spanish University System for 2021-2023.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

  • Akinci, Muge
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Salvadó, Gemma
  • González de Echávarri, José Maria
  • Suárez-Calvet, Marc
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: the COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods: two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results: in the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions: higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors., This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/GN17/10300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Milà Alomà, Marta
  • Vilor Tejedor, Natàlia, 1988-
  • Operto, Grégory
  • Falcón, Carles
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 ., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2021 SGR 00913. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation-Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 Grant SLT002/16/00201). OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I) and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). EA-U is supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), a “Ramón y Cajal” fellowship (RYC2018-026053-I) and by a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). MS-C receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JD-G holds a “Ramón y Cajal” fellowship (RYC-2013-13054).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults

  • Blackman, Jonathan
  • Stankeviciute, Laura
  • Arenaza Urquijo, Eider M.
  • Suárez-Calvet, Marc
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • Iranzo, Alejandro
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
  • European Prevention of Alzheimer’s Disease (EPAD) Consortium
Sleep abnormalities are prevalent in Alzheimer's disease, with sleep quality already impaired at its preclinical stage. Epidemiological and experimental data point to sleep abnormalities contributing to the risk of Alzheimer's disease. However, previous studies are limited by either a lack of Alzheimer's disease biomarkers, reduced sample size or cross-sectional design. Understanding if, when, and how poor sleep contributes to Alzheimer's disease progression is important so that therapies can be targeted to the right phase of the disease. Using the largest cohort to date, the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, we test the hypotheses that poor sleep is associated with core Alzheimer's disease CSF biomarkers cross-sectionally and predicts future increments of Alzheimer's disease pathology in people without identifiable symptoms of Alzheimer's disease at baseline. This study included 1168 adults aged over 50 years with CSF core Alzheimer's disease biomarkers (total tau, phosphorylated tau and amyloid-beta), cognitive performance, and sleep quality (Pittsburgh sleep quality index questionnaire) data. We used multivariate linear regressions to analyse associations between core Alzheimer's disease biomarkers and the following Pittsburgh sleep quality index measures: total score of sleep quality, binarized score (poor sleep categorized as Pittsburgh sleep quality index > 5), sleep latency, duration, efficiency and disturbance. On a subsample of 332 participants with CSF taken at baseline and after an average period of 1.5 years, we assessed the effect of baseline sleep quality on change in Alzheimer's disease biomarkers over time. Cross-sectional analyses revealed that poor sleep quality (Pittsburgh sleep quality index total > 5) was significantly associated with higher CSF t-tau; shorter sleep duration (<7 h) was associated with higher CSF p-tau and t-tau; and a higher degree of sleep disturbance (1-9 versus 0 and >9 versus 0) was associated with lower CSF amyloid-beta. Longitudinal analyses showed that greater sleep disturbances (1-9 versus 0 and >9 versus 0) were associated with a decrease in CSF Aβ42 over time. This study demonstrates that self-reported poor sleep quality is associated with greater Alzheimer's disease-related pathology in cognitively unimpaired individuals, with longitudinal results further strengthening the hypothesis that disrupted sleep may represent a risk factor for Alzheimer's disease. This highlights the need for future work to test the efficacy of preventive practices, designed to improve sleep at pre-symptomatic stages of disease, on reducing Alzheimer's disease pathology., O.G.-R. receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). M.S.-C. receives funding from Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme grant IJC2018-037478-I). N.V.-T. is funded by a Spanish Ministry of Science, Innovation and Universities postdoctoral grant (Juan de la Cierva programmegrant FJC2018-038085-I). E.M.A.-U. holds a ‘Ramón y Cajal’ fellowship (RYC2018-026053-I) and a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). J.B. receives funding from Alzheimer’s Research UK (supported by the Margaret Jost Fellowship and the Don Thoburn Memorial Scholarship) and the David Telling Charitable Trust, and E.C. has received funding from BRACE and ARUK (Bristol & Bath Network).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort

  • Canals-Gispert, Lidia
  • Cañas-Martínez, Alba
  • Huesa, Gema
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Arenaza Urquijo, Eider M.
  • Cirillo, Davide
  • Schumacher Dimech, Annemarie
  • Iulita, Maria Florencia
  • Novakova Martinkova, Julie
  • Tartaglia, Maria Carmela
  • Quevenco, Frances-Catherine
  • Santuccione Chadha, Antonella
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Ferretti, Maria Teresa
  • Fauria, Karine
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men and women in clinical trials and data reporting. Methods: This study aims to analyze gender differences in sociodemographic factors associated with the willingness to participate in clinical trials and undergo specific procedures in the context of an Alzheimer's disease prevention research cohort. 2544 cognitively unimpaired participants from the ALFA parent cohort (age 45-75 years) of the Barcelonaβeta Brain Research Center were contacted through a structured phone call to determine their willingness to participate in Alzheimer's disease clinical trials and undergo trial-related procedures (magnetic resonance imaging, lumbar puncture, positron emission tomography, and cognitive assessment). Sociodemographic data on education, occupational attainment, civil and caregiver status were gathered. Stepwise logistic regression models were performed in order to study the interaction between gender and sociodemographic factors in the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Results: 1,606 out of the 2,544 participants were women (63.1%). Women were significantly younger and had lower educational attainment compared with men. In addition, women were more likely to be caregivers, single and unemployed. Women showed a significantly lower willingness than men to participate in a clinical trial (p = 0.003) and to undergo a lumbar puncture (p < 0.001). Single women were less willing to participate in clinical trials than single men (p = 0.041). Regarding clinical trial-related procedures, women with higher years of education were significantly less willing to undergo a lumbar puncture (p = 0.031). Conclusion: We found gender differences regarding the sociodemographic factors that predict the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Our results highlight the urgent need to design recruitment strategies accounting for gender-related factors, particularly those related to marital status and education., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004. JNM is supported by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) "A way to make Europe"), and receives the support of a fellowship from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). EMAU receives funding from the Alzheimer’s Association (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and from the Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2019-111514RA-I00 and RYC2018-026053-I, co-funded by the European Social Fund (FSE)). GSB receives funding from the Ministry of Science and Innovation/Spanish Research Agency (PID2020-119556RA-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033/FEDER, UE). ABS receives funding from the Global Brain Health Institute (GBHI), Alzheimer's Association, Alzheimer's Society (GBHI ALZ UK-21–737797).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Physical activity changes during midlife link to brain integrity and amyloid burden

  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Garcia Prat, Marina
  • Deulofeu, Carme
  • Fauria, Karine
  • García Aymerich, Judith
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Introduction: Evidence suggests that midlife physical activity may reduce Alzheimer's disease (AD) risk. In at-risk individuals, we investigated midlife physical activity changes in relation to AD-related pathologies. Methods: We included 337 cognitively unimpaired adults with baseline and follow-up physical activity evaluations within 4.07 ± 0.84 years. We performed multiple regressions considering follow-up amyloid-PET burden and MRI-based medial temporal lobe cortical thickness as outcomes. Independent variables encompassed changes in adherence to World Health Organization (WHO)-recommended physical activity levels, activity amounts, and sedentary behavior (no activity reported). Results: Remaining sedentary was associated with lower cortical thickness compared to doing limited physical activity, maintaining adherence, or becoming adherent to WHO recommendations. Becoming adherent to recommendations was linked to lower amyloid burden compared to becoming non-adherent. Increased activity amounts showed a dose-dependent association with lower amyloid burden. Discussion: Increasing physical activity and new adherence to WHO recommendations could be key objectives for preventive strategies during midlife. Clinical trial registration information: Registered at Clinicaltrials.gov (identifier: NCT02485730). Highlights: Boosting physical activity in midlife may have beneficial effects in preclinical AD. Physical activity increases relate to lower Aβ burden in a dose-dependent manner. Remaining sedentary links to lower cortical thickness in AD-vulnerable structures. New adherence to WHO-recommended physical activity levels may enhance brain health., This work was supported by ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. EMA-U has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID). EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF) and EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lifetime stressful events associated with Alzheimer's Pathologies, neuroinflammation and brain structure in a risk enriched cohort

  • Palpatzis, Eleni
  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Garcia Prat, Marina
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Carboni, Margherita
  • Kollmorgen, Gwendlyn
  • Wild, Norbert
  • Fauria, Karine
  • Falcón, Carles
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Objective: Along with the known effects of stress on brain structure and inflammatory processes, increasing evidence suggest a role of chronic stress in the pathogenesis of Alzheimer's disease (AD). We investigated the association of accumulated stressful life events (SLEs) with AD pathologies, neuroinflammation, and gray matter (GM) volume among cognitively unimpaired (CU) individuals at heightened risk of AD. Methods: This cross-sectional cohort study included 1,290 CU participants (aged 48-77) from the ALFA cohort with SLE, lumbar puncture (n = 393), and/or structural magnetic resonance imaging (n = 1,234) assessments. Using multiple regression analyses, we examined the associations of total SLEs with cerebrospinal fluid (1) phosphorylated (p)-tau181 and Aβ1-42/1-40 ratio, (2) interleukin 6 (IL-6), and (3) GM volumes voxel-wise. Further, we performed stratified and interaction analyses with sex, history of psychiatric disease, and evaluated SLEs during specific life periods. Results: Within the whole sample, only childhood and midlife SLEs, but not total SLEs, were associated with AD pathophysiology and neuroinflammation. Among those with a history of psychiatric disease SLEs were associated with higher p-tau181 and IL-6. Participants with history of psychiatric disease and men, showed lower Aβ1-42/1-40 with higher SLEs. Participants with history of psychiatric disease and women showed reduced GM volumes in somatic regions and prefrontal and limbic regions, respectively. Interpretation: We did not find evidence supporting the association of total SLEs with AD, neuroinflammation, and atrophy pathways. Instead, the associations appear to be contingent on events occurring during early and midlife, sex and history of psychiatric disease. ANN NEUROL 2024;95:1058-1068., The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). This work has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. MS-C is funded by a fellowship from “la Caixa” Foundation (ID 100010434). OG-R is supported by the Spanish Ministry of Science and Innovation—State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR. The Roche NeuroToolKit is a panel of robust prototype assays used for investigational purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults

  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Operto, Grégory
  • Fuentes-Julián, Sherezade
  • Deulofeu, Carme
  • Sánchez-Benavides, Gonzalo
  • Milà-Alomà, Marta
  • Grau-Rivera, Oriol
  • Gramunt, Nina
  • Navarro, Arcadi
  • Minguillón, Carolina
  • Fauria, Karine
  • Suridjan, Ivonne
  • Kollmorgen, Gwendlyn
  • Bayfield, Anna
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Arenaza-Urquijo, Eider M.
Background and Objectives Increased anxious-depressive symptomatology is observed in the preclinical stage of Alzheimer disease (AD), which may accelerate disease progression. We investigated whether β-amyloid, cortical thickness in medial temporal lobe structures, neuroinflammation, and sociodemographic factors were associated with greater anxious-depressive symptoms during the COVID-19 confinement. Methods This retrospective observational study included cognitively unimpaired older adults from the Alzheimer's and Families cohort, the majority with a family history of sporadic AD. Participants performed the Hospital Anxiety and Depression Scale (HADS) during the COVID-19 confinement. A subset had available retrospective (on average: 2.4 years before) HADS assessment, amyloid [18F] flutemetamol PET and structural MRI scans, and CSF markers of neuroinflammation (interleukin-6 [IL-6], triggering receptor expressed on myeloid cells 2, and glial fibrillary acidic protein levels). We performed multivariable linear regression models to investigate the associations of prepandemic AD-related biomarkers and sociodemographic factors with HADS scores during the confinement. We further performed an analysis of covariance to adjust by participants' prepandemic anxiety-depression levels. Finally, we explored the role of stress and lifestyle changes (sleep patterns, eating, drinking, smoking habits, and medication use) on the tested associations and performed sex-stratified analyses. Results We included 921 (254 with AD biomarkers) participants. β-amyloid positivity (B = 3.73; 95% CI = 1.1 to 6.36; p = 0.006), caregiving (B = 1.37; 95% CI 0.24–2.5; p = 0.018), sex (women: B = 1.95; 95% CI 1.1–2.79; p < 0.001), younger age (B = −0.12; 95% CI −0.18 to −0.052; p < 0.001), and lower education (B = −0.16; 95% CI −0.28 to −0.042; p = 0.008) were associated with greater anxious-depressive symptoms during the confinement. Considering prepandemic anxiety-depression levels, we further observed an association between lower levels of CSF IL-6 (B = −5.11; 95% CI −10.1 to −0.13; p = 0.044) and greater HADS scores. The results were independent of stress-related variables and lifestyle changes. Stratified analysis revealed that the associations were mainly driven by women. Discussion Our results link AD-related pathophysiology and neuroinflammation with greater anxious-depressive symptomatology during the COVID-19-related confinement, notably in women. AD pathophysiology may increase neuropsychiatric symptomatology in response to stressors. This association may imply a worse clinical prognosis in people at risk for AD after the pandemic and thus deserves to be considered by clinicians., This research was supported by Alzheimer's Association research grants (AARG 2019-AARG-644641 and AARG 2019-AARG-644641-RAPID) to E.M. Arenaza-Urquijo. E.M. Arenaza-Urquijo holds a Ramón y Cajal fellowship (RYC2018-026053-I) and a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from la Caixa Foundation (LCF/PR/GN17/10300004), the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

  • Akinci, Muge
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Salvadó, Gemma
  • González de Echávarri, José Maria
  • Suárez-Calvet, Marc
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: the COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods: two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results: in the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions: higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors., This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/GN17/10300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort

  • Canals-Gispert, Lidia
  • Cañas-Martínez, Alba
  • Huesa, Gema
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Arenaza Urquijo, Eider M.
  • Cirillo, Davide
  • Schumacher Dimech, Annemarie
  • Iulita, Maria Florencia
  • Novakova Martinkova, Julie
  • Tartaglia, Maria Carmela
  • Quevenco, Frances-Catherine
  • Santuccione Chadha, Antonella
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Ferretti, Maria Teresa
  • Fauria, Karine
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men and women in clinical trials and data reporting. Methods: This study aims to analyze gender differences in sociodemographic factors associated with the willingness to participate in clinical trials and undergo specific procedures in the context of an Alzheimer's disease prevention research cohort. 2544 cognitively unimpaired participants from the ALFA parent cohort (age 45-75 years) of the Barcelonaβeta Brain Research Center were contacted through a structured phone call to determine their willingness to participate in Alzheimer's disease clinical trials and undergo trial-related procedures (magnetic resonance imaging, lumbar puncture, positron emission tomography, and cognitive assessment). Sociodemographic data on education, occupational attainment, civil and caregiver status were gathered. Stepwise logistic regression models were performed in order to study the interaction between gender and sociodemographic factors in the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Results: 1,606 out of the 2,544 participants were women (63.1%). Women were significantly younger and had lower educational attainment compared with men. In addition, women were more likely to be caregivers, single and unemployed. Women showed a significantly lower willingness than men to participate in a clinical trial (p = 0.003) and to undergo a lumbar puncture (p < 0.001). Single women were less willing to participate in clinical trials than single men (p = 0.041). Regarding clinical trial-related procedures, women with higher years of education were significantly less willing to undergo a lumbar puncture (p = 0.031). Conclusion: We found gender differences regarding the sociodemographic factors that predict the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Our results highlight the urgent need to design recruitment strategies accounting for gender-related factors, particularly those related to marital status and education., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004. JNM is supported by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) "A way to make Europe"), and receives the support of a fellowship from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). EMAU receives funding from the Alzheimer’s Association (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and from the Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2019-111514RA-I00 and RYC2018-026053-I, co-funded by the European Social Fund (FSE)). GSB receives funding from the Ministry of Science and Innovation/Spanish Research Agency (PID2020-119556RA-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033/FEDER, UE). ABS receives funding from the Global Brain Health Institute (GBHI), Alzheimer's Association, Alzheimer's Society (GBHI ALZ UK-21–737797).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Physical activity changes during midlife link to brain integrity and amyloid burden

  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Garcia Prat, Marina
  • Deulofeu, Carme
  • Fauria, Karine
  • García Aymerich, Judith
  • Gispert López, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Introduction: Evidence suggests that midlife physical activity may reduce Alzheimer's disease (AD) risk. In at-risk individuals, we investigated midlife physical activity changes in relation to AD-related pathologies. Methods: We included 337 cognitively unimpaired adults with baseline and follow-up physical activity evaluations within 4.07 ± 0.84 years. We performed multiple regressions considering follow-up amyloid-PET burden and MRI-based medial temporal lobe cortical thickness as outcomes. Independent variables encompassed changes in adherence to World Health Organization (WHO)-recommended physical activity levels, activity amounts, and sedentary behavior (no activity reported). Results: Remaining sedentary was associated with lower cortical thickness compared to doing limited physical activity, maintaining adherence, or becoming adherent to WHO recommendations. Becoming adherent to recommendations was linked to lower amyloid burden compared to becoming non-adherent. Increased activity amounts showed a dose-dependent association with lower amyloid burden. Discussion: Increasing physical activity and new adherence to WHO recommendations could be key objectives for preventive strategies during midlife. Clinical trial registration information: Registered at Clinicaltrials.gov (identifier: NCT02485730). Highlights: Boosting physical activity in midlife may have beneficial effects in preclinical AD. Physical activity increases relate to lower Aβ burden in a dose-dependent manner. Remaining sedentary links to lower cortical thickness in AD-vulnerable structures. New adherence to WHO-recommended physical activity levels may enhance brain health., This work was supported by ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. EMA-U has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID). EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF) and EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Milà Alomà, Marta
  • Vilor Tejedor, Natàlia, 1988-
  • Operto, Grégory
  • Falcón, Carles
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 ., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2021 SGR 00913. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation-Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 Grant SLT002/16/00201). OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I) and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). EA-U is supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), a “Ramón y Cajal” fellowship (RYC2018-026053-I) and by a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). MS-C receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JD-G holds a “Ramón y Cajal” fellowship (RYC-2013-13054).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lifetime stressful events associated with Alzheimer's Pathologies, neuroinflammation and brain structure in a risk enriched cohort

  • Palpatzis, Eleni
  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Garcia Prat, Marina
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Carboni, Margherita
  • Kollmorgen, Gwendlyn
  • Wild, Norbert
  • Fauria, Karine
  • Falcón, Carles
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Objective: Along with the known effects of stress on brain structure and inflammatory processes, increasing evidence suggest a role of chronic stress in the pathogenesis of Alzheimer's disease (AD). We investigated the association of accumulated stressful life events (SLEs) with AD pathologies, neuroinflammation, and gray matter (GM) volume among cognitively unimpaired (CU) individuals at heightened risk of AD. Methods: This cross-sectional cohort study included 1,290 CU participants (aged 48-77) from the ALFA cohort with SLE, lumbar puncture (n = 393), and/or structural magnetic resonance imaging (n = 1,234) assessments. Using multiple regression analyses, we examined the associations of total SLEs with cerebrospinal fluid (1) phosphorylated (p)-tau181 and Aβ1-42/1-40 ratio, (2) interleukin 6 (IL-6), and (3) GM volumes voxel-wise. Further, we performed stratified and interaction analyses with sex, history of psychiatric disease, and evaluated SLEs during specific life periods. Results: Within the whole sample, only childhood and midlife SLEs, but not total SLEs, were associated with AD pathophysiology and neuroinflammation. Among those with a history of psychiatric disease SLEs were associated with higher p-tau181 and IL-6. Participants with history of psychiatric disease and men, showed lower Aβ1-42/1-40 with higher SLEs. Participants with history of psychiatric disease and women showed reduced GM volumes in somatic regions and prefrontal and limbic regions, respectively. Interpretation: We did not find evidence supporting the association of total SLEs with AD, neuroinflammation, and atrophy pathways. Instead, the associations appear to be contingent on events occurring during early and midlife, sex and history of psychiatric disease. ANN NEUROL 2024;95:1058-1068., The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). This work has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. MS-C is funded by a fellowship from “la Caixa” Foundation (ID 100010434). OG-R is supported by the Spanish Ministry of Science and Innovation—State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR. The Roche NeuroToolKit is a panel of robust prototype assays used for investigational purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults

  • Blackman, Jonathan
  • Stankeviciute, Laura
  • Arenaza Urquijo, Eider M.
  • Suárez-Calvet, Marc
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • Iranzo, Alejandro
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
  • European Prevention of Alzheimer’s Disease (EPAD) Consortium
Sleep abnormalities are prevalent in Alzheimer's disease, with sleep quality already impaired at its preclinical stage. Epidemiological and experimental data point to sleep abnormalities contributing to the risk of Alzheimer's disease. However, previous studies are limited by either a lack of Alzheimer's disease biomarkers, reduced sample size or cross-sectional design. Understanding if, when, and how poor sleep contributes to Alzheimer's disease progression is important so that therapies can be targeted to the right phase of the disease. Using the largest cohort to date, the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, we test the hypotheses that poor sleep is associated with core Alzheimer's disease CSF biomarkers cross-sectionally and predicts future increments of Alzheimer's disease pathology in people without identifiable symptoms of Alzheimer's disease at baseline. This study included 1168 adults aged over 50 years with CSF core Alzheimer's disease biomarkers (total tau, phosphorylated tau and amyloid-beta), cognitive performance, and sleep quality (Pittsburgh sleep quality index questionnaire) data. We used multivariate linear regressions to analyse associations between core Alzheimer's disease biomarkers and the following Pittsburgh sleep quality index measures: total score of sleep quality, binarized score (poor sleep categorized as Pittsburgh sleep quality index > 5), sleep latency, duration, efficiency and disturbance. On a subsample of 332 participants with CSF taken at baseline and after an average period of 1.5 years, we assessed the effect of baseline sleep quality on change in Alzheimer's disease biomarkers over time. Cross-sectional analyses revealed that poor sleep quality (Pittsburgh sleep quality index total > 5) was significantly associated with higher CSF t-tau; shorter sleep duration (<7 h) was associated with higher CSF p-tau and t-tau; and a higher degree of sleep disturbance (1-9 versus 0 and >9 versus 0) was associated with lower CSF amyloid-beta. Longitudinal analyses showed that greater sleep disturbances (1-9 versus 0 and >9 versus 0) were associated with a decrease in CSF Aβ42 over time. This study demonstrates that self-reported poor sleep quality is associated with greater Alzheimer's disease-related pathology in cognitively unimpaired individuals, with longitudinal results further strengthening the hypothesis that disrupted sleep may represent a risk factor for Alzheimer's disease. This highlights the need for future work to test the efficacy of preventive practices, designed to improve sleep at pre-symptomatic stages of disease, on reducing Alzheimer's disease pathology., O.G.-R. receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). M.S.-C. receives funding from Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme grant IJC2018-037478-I). N.V.-T. is funded by a Spanish Ministry of Science, Innovation and Universities postdoctoral grant (Juan de la Cierva programmegrant FJC2018-038085-I). E.M.A.-U. holds a ‘Ramón y Cajal’ fellowship (RYC2018-026053-I) and a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). J.B. receives funding from Alzheimer’s Research UK (supported by the Margaret Jost Fellowship and the Don Thoburn Memorial Scholarship) and the David Telling Charitable Trust, and E.C. has received funding from BRACE and ARUK (Bristol & Bath Network).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Psychological resilience trajectories after the COVID-19 pandemic: the role of lifestyle and psychosocial factors in a cohort at increased alzheimer's disease risk

  • Contador, Israel
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Fauria, Karine
  • Minguillón, Carolina
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
Purpose: This longitudinal cohort study evaluates whether lifestyle and psychosocial factors are associated with psychological resilience at two time points of COVID-19 pandemic. Moreover, we investigated the mediating role of perceived stress on these associations.Methods: A total of 677 cognitively unimpaired (CU) older adults at increased risk of Alzheimer's disease (AD) completed the Hospital Anxiety and Depression Scale (HADS). Based on the Reliable Change Index (RCI), HADS trajectories were defined at two intervals: (1) pre-pandemic-confinement (follow-up = 2,28 ± 0,84 years); (2) confinement-post-confinement (follow-up = 1,49 ± 0,12 years). Then, 4 trajectory groups were defined: Psychological Resilience (n = 448, stable or improve at both intervals), Descending (n = 84, stable/improve [interval 1]-worsen [interval 2]), Recovery (n = 59, worsening [interval 1], improvement [interval 2] ) and Non-resilient (n = 86, worsening at both intervals). Logistic regression models (LRM) were applied considering lifestyle (physical and leisure activities, sleep) and psychosocial factors (social relationships and emotional support) as predictors of psychological resilience trajectory (i.e., outcome) at both intervals. Finally, mediation analyses were carried out to test the effect of perceived stress on the relationships between the predictive factors and psychological resilience. Results: Our finding showed that most participants followed a psychological resilient trajectory (66,1%). LRMs indicated that higher physical activity level, a greater number of social interactions and longer sleep duration were significantly associated with a psychological resilience trajectory both at confinement and at the 1.5 years follow-up. Lastly, the mediation analyses suggested that these factors influence psychological resilience through the mitigation of perceived stress. Conclusion: These findings underscore the role of physical activity, social interactions and sleep quality to strengthen individuals' capacity to cope with stress during prolonged crisis such as the COVID-19 pandemic. These lifestyle and psychological factors may be valuable targets for public health strategies aimed to prevent mental health problems., Open access funding provided by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027. The ALFA study receives funding from "la Caixa" Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. EMAU receives funding from the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation-State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). OG-R receives funding from the Alzheimer's Association Research Fellowship Programme (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). GS-B is supported by the Spanish Ministry of Science and Innovation - State Research Agency. MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).I. Contador was supported by the European Union- "NextGenerationEU" through the Grant for the Requalification of the Spanish University System for 2021-2023.